ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "SLE"

  • Abstract Number: 672 • 2019 ACR/ARP Annual Meeting

    Mouse SLE Studies Do Not Describe Human SLE

    Ecem Sevim1, Linjia Jia 2, David Fernandez 3 and Michael Lockshin 4, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, Mary Kirkland Center for Lupus Research, New York, NY, 4Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY

    Background/Purpose: Although mouse models of systemic lupus erythematosus (SLE) are useful proxies for human illness, they are heterogeneous, and publications about mouse SLE may not…
  • Abstract Number: 1024 • 2019 ACR/ARP Annual Meeting

    Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells

    Sun Ah Kang1, Jennifer Rogers 2, Saira Sheikh 3, Megan Clowse 2, Lisa Criscione-Schreiber 2 and Barb Vilen 4, 1University of NOrth Carolina at Chapel Hlil, Chapel Hill, NC, 2Duke University, Durham, 3University of North Carolina, Chapel Hill, NC, 4University of North Carolina CHapel Hill, Chapel Hill, NC

    Background/Purpose:   Impaired clearance of cell debris allows nuclear self-antigens such as DNA to accumulate, bind autoreactive IgG and form immune complexes (IgG-ICs) in SLE.  We…
  • Abstract Number: 1579 • 2019 ACR/ARP Annual Meeting

    Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race

    Elena Gkrouzman1, Julia Davis-Porada 1, Mary Peng 2 and Kyriakos Kirou 2, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, New York, NY

    Background/Purpose: Risk of thrombosis is elevated in patients with systemic lupus erythematosus (SLE) compared to healthy individuals, especially during the first year after diagnosis. The…
  • Abstract Number: 2034 • 2019 ACR/ARP Annual Meeting

    Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement

    Yi Li1, Hao Li 2, Shui Lian Yu 3, Vasileios Kyttaris 4 and George Tsokos 4, 1BIDMC, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 3The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (People's Republic), 4Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: We have previously shown that DN T cells are expanded in both lupus-prone mice and patients with SLE and we have demonstrated that this…
  • Abstract Number: 64 • 2019 ACR/ARP Annual Meeting

    Rab4A Controls mTOR Pathway Activation, Pro-inflammatory Lineage Development, and Disease Pathogenesis in Lupus-prone Mice

    Nick Huang1, Zhiwei Lai 2, Brandon Wyman 2, Thomas Winans 2, Manuel Duarte 2, Joshua Lewis 2, Mark Haas 3, Laurence Morel 4 and Andras Perl 5, 1Upstate Medical University, Syracuse, NY, 2Upstate Medical University, Syracuse, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4University of Florida, Gainesville, FL, 5SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: Mouse models of SLE have been indispensable tools for studying disease pathogenesis; however, each model only recapitulates limited aspects of lupus. SLE1.2.3. (TC) mice…
  • Abstract Number: 673 • 2019 ACR/ARP Annual Meeting

    Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center

    Elizabeth Graef1, Daniel Magliulo 1, Norris Hollie 1, Chelsea Marcus 2 and Vasileios Kyttaris 3, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Boston, 3Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: While lymphadenopathy and/or lymphadenitis (LAD) is considered a relatively common clinical finding in SLE patients, its clinical significance is poorly understood. Previous studies described…
  • Abstract Number: 1025 • 2019 ACR/ARP Annual Meeting

    Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity

    Kieran Manion1, Zahi Touma 2, Dennisse Bonilla 2, Dafna Gladman 3, Murray Urowitz 2 and Joan Wither 4, 1Krembil Research Institute, Toronto, ON, Canada, 2University Health Network, University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, U of Toronto, Toronto, ON, Canada, 4University Health Network, Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: SLE is a chronic autoimmune disorder in which periods of relative disease inactivity are punctuated by flares that present with increased inflammation and tissue…
  • Abstract Number: 1586 • 2019 ACR/ARP Annual Meeting

    All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database

    Rashmi Dhital1, Dilli Ram Poudel 2, Ramesh Kumar Pandey 3 and Paras Karmacharya 4, 1Reading Hospital ,PA, Shillington, PA, 2University of Pennsylvania, Philadelphia, 3Fox Chase Hospital, Philadelphia, 4Reading Hospital, Mayo Clinic, Rochester

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disorder with variable presentation. While several studies have outlined the risk factors for hospitalization and…
  • Abstract Number: 2036 • 2019 ACR/ARP Annual Meeting

    Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus

    Jie An1, Bhargavi Duvvuri 1, Xizhang Sun 1, Lena Tanaka 1, Christian Lood 1 and Keith Elkon 1, 1University of Washington, Seattle

    Background/Purpose: Approximately 70% of patients with Systemic Lupus Erythematosus (SLE) show a striking Type I Interferon (IFN-I) signature in peripheral blood. Although we have some…
  • Abstract Number: 65 • 2019 ACR/ARP Annual Meeting

    CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE

    Samantha Chalmers1, Sayra Garcia 1, Rajalakshmy Ayilam Ramachandran 2, Chandra Mohan 2, Jeanette Ampudia 3, Cherie Ng 3, Stephen Connelly 3 and Chaim Putterman 4, 1Albert Einstein College of Medicine, Bronx, NY, 2University of Houston, Houston, 3Equillium, Inc, San Diego, CA, 4Albert Einstein College of Medicine, New York, NY

    Background/Purpose: T cells are an important contributor the pathogenesis of SLE and its various end organ manifestations. Thus, they present themselves as potential therapeutic targets;…
  • Abstract Number: 678 • 2019 ACR/ARP Annual Meeting

    Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease

    Martin Aringer1, Ralph Brinks 2, Karen Costenbader 3, David Daikh 4, Dimitrios Boumpas 5, David Jayne 6, Diane Kamen 7, Marta Mosca 8, Rosalind Ramsey-Goldman 9, Josef Smolen 10, David Wofsy 11, Betty Diamond 12, Søren Jacobsen 13, W Joseph McCune 14, Guillermo Ruiz-Irastorza 15, Matthias Schneider 16, Murray Urowitz 17, George Bertsias 18, Bimba Hoyer 19, Nicolai Leuchten 20, Chiara Tani 21, Sara K. Tedeschi 22, Zahi Touma 17, Branimir Anic 23, Florence Assan 24, Daniel TM Chan 25, Ann E Clarke 26, Mary Crow 27, László Czirják 28, Andrea Doria 29, Winfried Graninger 30, Bernadette Halda-Kiss 31, Sarfaraz Hasni 32, Peter Izmirly 33, Michelle Jung 26, Gabor Kumanovics 31, Xavier Mariette 34, Ivan Padjen 23, Jose Maria Pego-Reigosa 35, Juanita Romero-Diaz 36, Iñigo Rua Figueroa 37, Raphaèle Seror 24, Georg Stummvoll 10, Yoshiya Tanaka 38, Maria Tektonidou 39, Carlos Vasconcelos 40, Edward Vital 41, Daniel Wallace 42, Sule Yavuz 43 Raymond Naden 44, Thomas Dörner 45 and Sindhu R. Johnson 46, 1Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, 2Department of Rheumatology and Hiller Research Unit of Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4University of California at San Francisco and VA Medical Center, San Francisco, CA, 5University of Athens, Athens, Greece, 6Vasculitis and Lupus Clinic, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom, 7Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 8Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, 9Northwestern University, Chicago, IL, 10Medical University of Vienna, Vienna, Austria, 11UCSF, San Francisco, 12Feinstein Institutes for Medical Research, Manhasset, 13Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, 14University of Michigan, Ann Arbor, MI, 15Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, 16Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, 17University Health Network, University of Toronto, Toronto, ON, Canada, 18University of Crete, Rheumatology, Clinical Immunology and Allergy Unit, Heraklion, Greece, 19University of Schleswig-Holstein at Kiel, and Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Kiel, Germany, 20University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 21Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, 22Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 23UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, 24Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, 25University of Hong Kong, Hong Kong, Hong Kong, 26University of Calgary, Calgary, AB, Canada, 27Hospital for Special Surgery, New York, NY, 28Dept. of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, 29University and Azienda Ospedaliera of Padova, Padova, Italy, 30Medical University of Graz, Graz, Austria, 31University of Pécs, Pécs, Hungary, 32NIAMS, National Institutes of Health, Bethesda, MD, 33NYU School of Medicine, New York, 34Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 35Complexo Hospitalario Universitario, Vigo, Spain, 36Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, 37Hospital Doctor Negrin, Las Palmas, 38University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 39First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, 40University of Porto, UMIB Abel Salazar Biomedical Sciences Institute, Porto, Portugal, 41University of Leeds, Leeds, United Kingdom, 42Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, 43Uppsala University, Istanbul, Turkey, 44McMaster University, Hamilton, ON, Canada, 45Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 46Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada

    Background/Purpose: The EULAR/ACR 2019 Classification Criteria for SLE have been validated in an international cohort of 696 SLE patients and 574 non-SLE patients with a…
  • Abstract Number: 1033 • 2019 ACR/ARP Annual Meeting

    Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus

    Ye Cao1, Stephen Alves 2, Corine Sinnette 3, Cameron Speyer 3, Gregory Keras 1, Yujie Qu 2, Joshua Keegan 4, James Lederer 4, Deepak Rao 3 and Karen Costenbader 3, 1Brigham and Women's Hospital, Boston, 2Merck, boston, 3Brigham and Women's Hospital, Boston, MA, 4BWH, Boston

    Background/Purpose: The immune cell subsets most altered early in SLE disease course remain unclear. Defining abnormalities in lymphocyte populations in patients with new-onset SLE may…
  • Abstract Number: 1591 • 2019 ACR/ARP Annual Meeting

    Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophophosphamide

    Martha Tsaliki 1, Kristi Koelsch 1, Ambre Chambers 1, Mitali Talsania 2, Eliza Chakravarty 3 and Robert Scofield3, 1University of Oklahoma health Sciences Center, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoam City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Treatment of systemic lupus erythematosus (SLE) with cyclophosphamide is associated with premature menopause, especially those at an older age of treatment and those receiving…
  • Abstract Number: 2041 • 2019 ACR/ARP Annual Meeting

    Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease

    Juliana Imgenberg-Kreuz1, Christopher Sjöwall 2, Martina Frodlund 2, Iva Gunnarsson 3, Elisabet Svenungsson 4 and Dag Leonard 1, 1Department of Medical Sciences, Section of Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, 2Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, 3Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of ischemic heart disease (IHD). Altered methylation patterns have been reported both in SLE,…
  • Abstract Number: 66 • 2019 ACR/ARP Annual Meeting

    Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation

    Samantha Chalmers1, Sayra Garcia 1, Jeanette Ampudia 2, Cherie Ng 2, Stephen Connelly 2 and Chaim Putterman 3, 1Albert Einstein College of Medicine, Bronx, NY, 2Equillium, Inc, San Diego, CA, 3Albert Einstein College of Medicine, New York, NY

    Background/Purpose: CD6 is a co-stimulatory receptor on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presentation cells…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology